Sanofi reports an historic step for the potential first US OTC switch of an erectile dysfunction drug while refusing even the slightest nod toward an imminent spin-out of its consumer business, a key driver in its 8.6% net sales growth for its latest quarter.
After cough/cold sales led the way in the first quarter at 118.2% growth for 17% overall consumer business growth to...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?